**RESEARCH ARTICLE**

**CO₂ insufflation versus air insufflation for endoscopic submucosal dissection: A meta-analysis of randomized controlled trials**

**Xuan Li¹,²*, Hao Dong³*, Yifeng Zhang¹,², Guoxin Zhang¹,²**

¹ Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ² Department of Gastroenterology, the First School of Clinical Medicine of Nanjing Medical University, Nanjing, China, ³ Department of Cardiology, the Second Hospital of Nanjing, Nanjing, China

* These authors contributed equally to this work.
† These authors are co-first authors on this work

* guoxinz@njmu.edu.cn

**Abstract**

**Background**
Carbon dioxide (CO₂) insufflation is increasingly used for endoscopic submucosal dissection (ESD) owing to the faster absorption of CO₂ as compared to that of air. Studies comparing CO₂ insufflation and air insufflation have reported conflicting results.

**Objectives**
This meta-analysis is aimed to assess the efficacy and safety of use of CO₂ insufflation for ESD.

**Methods**
Clinical trials of CO₂ insufflation versus air insufflation for ESD were searched in PubMed, Embase, the Cochrane Library and Chinese Biomedical Literature Database. We performed a meta-analysis of all randomized controlled trials (RCTs).

**Results**
Eleven studies which compared the use of CO₂ insufflation and air insufflation, with a combined study population of 1026 patients, were included in the meta-analysis (n = 506 for CO₂ insufflation; n = 522 for air insufflation). Abdominal pain and VAS scores at 6h and 24h post-procedure in the CO₂ insufflation group were significantly lower than those in the air insufflation group, but not at 1h and 3h after ESD. The percentage of patients who experienced pain 1h and 24h post-procedure was obviously decreased. Use of CO₂ insufflation was associated with lower VAS scores for abdominal distention at 1h after ESD, but not at 24h after ESD. However, no significant differences were observed with respect to postoperative transcutaneous partial pressure carbon dioxide (PtcCO₂), arterial blood carbon dioxide partial pressure (PaCO₂), oxygen saturation (SpO₂%), abdominal circumference, hospital
stay, white blood cell (WBC) counts, C-Reactive protein (CRP) level, dosage of sedatives used, incidence of dysphagia and other complications.

**Conclusion**

Use of CO\textsubscript{2} insufflation for ESD was safe and effective with regard to abdominal discomfort, procedure time, and the residual gas volume. However, there appeared no significant differences with respect to other parameters namely, PtcCO\textsubscript{2}, PaCO\textsubscript{2}, SpO\textsubscript{2}%, abdominal circumference, hospital stay, sedation dosage, complications, WBC, CRP, and dysphagia.

**Introduction**

Endoscopic submucosal dissection (ESD) allows lesions to be dissected and resected directly along the submucosal (sm) layer with use of an electrosurgical knife. With rapid advances in endoscopic techniques, ESD has become an invaluable tool in the treatment of early neoplasms of the gastrointestinal tract, particularly for large lesions[1]. However, this procedure is time-consuming and requires special endoscopic experience. The incidence of complications such as perforations, hemorrhage, and abdominal discomfort has also increased as a direct result[2].

Insufflation is required to achieve adequate visualization during ESD. Postoperatively, the gas is not absorbed immediately and remains in the gastrointestinal tract, which can cause abdominal pain and distension. Carbon dioxide (CO\textsubscript{2}) is rapidly cleared from the small bowel and excreted through the lungs, thus allowing the bowel to deflate quickly[3]. The benefits of use of CO\textsubscript{2} over air were first pointed out by Rogers [4]. It is generally believed that use of CO\textsubscript{2} insufflation is associated with less severe pneumoperitoneum, abdominal pain and abdominal distension[5, 6]. Recent clinical studies have shown that CO\textsubscript{2} insufflation for ESD is safe and effective; however, Maeda et al[7] observed no significant difference with respect to post-procedural abdominal pain or discomfort between the CO\textsubscript{2} insufflation and air insufflation groups. In addition, two meta-analyses of studies which compared the use of CO\textsubscript{2} insufflation versus air insufflation for gastrointestinal endoscopy and endoscopic retrograde cholangiopancreatography (ERCP) reinforced the advantages of CO\textsubscript{2} insufflation (lower post-procedural pain and bowel distension); however, they did not find any advantage with respect to arterial blood CO\textsubscript{2} partial pressure (PaCO\textsubscript{2}) and transcutaneous partial pressure CO\textsubscript{2} (PtcCO\textsubscript{2}) levels[8, 9].

Since then, numerous randomized controlled trials (RCTs) have addressed the role of abdominal discomfort and CO\textsubscript{2} variation; however, other advantages of use of CO\textsubscript{2} insufflation have not been adequately investigated. Few RCTs have assessed comprehensive indicators, such as the dosage of sedative drugs, procedure time and incidence of complications. Additionally, the number of patients in these RCTs were largely inadequate. Although the superiority of CO\textsubscript{2} insufflation with respect to postoperative abdominal discomfort is backed by strong evidence from RCTs, the safety and efficacy of CO\textsubscript{2} insufflation for ESD treatment has not been assessed by a meta-analysis. We, therefore, sought to assess the safety and efficacy of use of CO\textsubscript{2} insufflation in patients undergoing ESD by performing a meta-analysis.

**Method**

**Literature search**

A literature search for relevant studies was conducted on online databases, Pubmed, Excerpta Medica Database (EMBASE), The Cochrane Library, Science Citation Index Expanded, and
Chinese Biomedical Literature Database (Sinomed). All studies published as of January 2017 were eligible for inclusion. No restriction was imposed with respect to the language of publication or type of article. The following free-text terms and MeSH terms were used to retrieve studies: “carbon dioxide,” “ESD,” and “air”. The search strategy is summarized in S1 Table.

Study selection and data extraction

Only RCTs that compared the use of CO\textsubscript{2} insufflation with that of insufflation for ESD were selected. Two reviewers (Li X & Dong H) independently summarized information and data from each study using a standardized format. Any disagreement over study selection was resolved by referring to the adjudicating senior author (Zhang GX). Duplicate articles were excluded with the use of the software package Endnote X4 (reference management software). The title and abstract of the selected articles were screened to exclude articles that did not qualify the inclusion criteria, followed by a full text review of all eligible articles. In the event of lack of original data in the article, the respective authors were contacted to request further information.

Outcomes

The primary outcomes for this analysis were (i) visual analogue scale (VAS) score for pain; (ii) percentage of patients without pain at various time points after ESD; and (iii) PtCO\textsubscript{2} and PaCO\textsubscript{2} levels at different time points after ESD. The secondary outcomes were: abdominal distention, abdominal circumference, oxygen saturation (SpO\textsubscript{2}%), total procedure time; average hospital stay; dose of sedative drugs; incidence of complications (pneumonia, hemorrhage, perforation, and emphysema); clinical course (anal exsufflation, dysphagia, residual gas, and Mallory-Weiss tear); laboratory examination (white blood cell count [WBC] and C Reactive Protein [CRP] level).

Quality assessment

Two authors (Li X and Dong H) independently evaluated the methodological quality of the included studies with use of the ‘risk of bias’ assessment tool from the Cochrane Handbook for Systematic Reviews of Interventions[10]. The following aspects of the methodology were assessed: random sequence generation, concealment of allocation, blinding of subjects and personnel, blinding of outcome assessment, completeness of reporting of outcomes data, potential reporting bias, and other sources of bias. The studies were divided into three groups based on the assessed risk of bias: high risk of bias, low risk of bias, and unclear. Disagreements were resolved by referring to the third author (Zhang GX).

Statistical analysis

Meta-analyses were conducted with Review Manager 5.3 (Cochrane Collaboration, Oxford, UK). The random-effects model was used for all analyses owing to clinical heterogeneity among the selected studies[11]. The outcome variables were dichotomous. Risk ratios (RR) with 95% confidence intervals (CIs) were calculated by Mantel-Haenszel method. For continuous variables, mean difference (MD) with 95% CIs were calculated with inverse variance method[12]. For continuous outcomes measured on different scales, standardized mean difference (SMD) with 95% CI is reported. Heterogeneity among the selected trials was assessed with $I^2$ measure of inconsistency (cutoff level of $I^2 = 50\%$). Sensitivity analyses were performed only for high-quality studies. If sufficient data were available, publication bias was assessed with use of funnel plots.
Results
Identification and characteristics of studies
A total of 37 records were retrieved on initial search on electronic databases, including The Cochrane Library ($n = 7$), PubMed ($n = 9$), EMBASE ($n = 12$), Chinese Biomedical Literature Database ($n = 6$), and manual search of the references of the included RCTs ($n = 1$). Eighteen duplicates and four non-relevant articles were excluded after review of titles and abstracts. After a review of full texts, 2 articles with retrospective study design and an uncontrolled study were excluded. Finally, eleven publications were included in this meta-analysis; of these, ten were original research articles published in journals while one was a conference abstract. Fig 1 illustrates the process of literature search and study selection.

The characteristics of included studies are summarized in Table 1. A total of 1026 patients were involved; 506 were administered CO$_2$ insufflation and 522 were administered air insufflation. In the third trial, 30 participants (12 from the CO$_2$ group and 18 from the air group) particularly underwent further analysis, including PaCO$_2$, procedure time, and sedative drugs dosage. All studies were conducted in Asia: eight in Japan[7, 13–18], three in China[19–21], and one in South Korea[22]. ESD equipment used in the trials included Olympus Optical Co [13, 15], Olympus GIF- Q260][18, 21, 22], Olympus XGIF-2T240 M[7], Olympus 165[14], Pentex 2940[19], and Olympus CV-260SL[20]. For two articles, relevant details were not mentioned[16, 17].

![Fig 1. Flow diagram of studies identified, included, and excluded.](https://doi.org/10.1371/journal.pone.0177909.g001)
Table 1. Characteristics of the included studies.

| Study          | Recruitment period | Country | Design                  | Endoscope                  | Sample size (CO₂/Air) | Mean age (CO₂/Air) | Gender |
|----------------|--------------------|---------|-------------------------|----------------------------|-----------------------|--------------------|--------|
| Nonaka et al   | Mar 2007-Jul 2008  | Japan   | Prospective,RCT, Double-blind | Olympus Optical Co         | 89(45/44)             | 68.5±8.8/67.6 ±8.0| 39/38  |
| Maeda et al    | Feb 2011-Sep 2011  | Japan   | Prospective,RCT, Double-blind | Olympus XGIF-2T240 M       | 102(54/48)            | 72.5±9.0/72.0 ±10.2| 40/35  |
| Takada et al   | Jan 2009-Dec 2009  | Japan   | Prospective,RCT, Double-blind | Olympus 165               | 87(36/51)             | 74.0±8.7/70.0 ±12.0| 22/36  |
| X Liu et al    | Jan 2013-Dec 2014  | China   | Prospective,RCT, Double-blind | Pentax 2940              | 80(40/40)             | 58.4±10.8/57.2 ±12.6| 21/25  |
| L Zhan et al   | Jan 2012-May 2014  | China   | Prospective,RCT, Double-blind | Olympus CV-260SL          | 158(75/83)            | 39.6±7.1/40.2 ±6.5 | 40/45  |
| HK Feng et al  | May 2011-Mar 2013  | China   | Prospective,RCT, Double-blind | Olympus GIF—260J          | 97(56/41)             | Not reported       | Not reported |
| Kim et al      | May 2012-Aug 2014  | Koran   | Prospective,RCT, Double-blind | Olympus GIF-Q260J         | 102(50/52)            | 81.8±9.5/62.0 ±7.5 | 34/16  |
| Saito et al    | Nov 2004-May 2005  | Japan   | Prospective,RCT, Double-blind | Olympus Optical Co        | 70(35/35)             | Not reported       | Not reported |
| Mosby et al    | Not reported       | Japan   | Prospective,RCT, Double-blind | Not reported              | 110(55/55)            | Not reported       | Not reported |
| Onogi et al    | Jan 2009-Dec 2009  | Japan   | Prospective,RCT, Double-blind | Not reported              | 87(36/51)             | Not reported       | Not reported |
| Maeda et al    | Feb 2011-May 2012  | Japan   | Prospective,RCT, Double-blind | Olympus GIF-Q260J         | 46(24/22)             | 67.5±5.8/72.0 ±7.2 | 21/3   |

https://doi.org/10.1371/journal.pone.0177909.t001

Risk of bias assessment

Cochrane risk of bias summary is shown in Fig 2. In six RCTs, group allocation was based on computer generated random number sequence or with use of an opaque envelope[7, 14, 16, 18, 20, 22]; for four RCTs, details of allocation concealment methods were not reported in

a:  

![Random sequence generation (selection bias)](https://example.com)  

b:  

![Allocation concealment (selection bias)](https://example.com)

Fig 2. Results of quality assessment by Cochrane risk of bias. a. each risk of bias item presented as percentages across all included studies. b. each risk of bias item for each included study.

https://doi.org/10.1371/journal.pone.0177909.g002
adequate detail [13, 17, 19, 21]. With regard to information bias, both the participants and the endoscopists were blinded to the type of gas used [7, 13, 14, 16, 18–22], with the exception of the eighth and the tenth study [15, 17]. Immediate post-procedure assessment was performed by an assistant blinded to group allocation [7, 14–16, 19–22], with the exception of the tenth study [17]. In the seventh study, 8 patients who did not complete questionnaires were excluded from the final analyses [22]. For the other trials rated as ‘low risk of bias’ had no participant loss [7, 13–17, 19–21]. Most studies included were rated as ‘high risk of bias’ [13–18, 20, 21], because of selective reporting of outcomes.

Outcome measures

Data on PtcCO$_2$ levels [7, 13, 14, 17, 18], PaCO$_2$ levels [14, 15, 19–21] was reported by five studies each. Data on SpO$_2\%$ after ESD was reported for four studies [7, 13, 14, 18]. The 100 mm VAS was used to grade abdominal pain [7, 16, 18–20] and abdominal distention [20, 22]. The scale ranges from 0 (no pain) to 100 (maximal pain) [24]. The percentage of patients with abdominal pain was also evaluated [7, 21, 22]. Only three studies reported data on median hospital stay [7, 14, 21]. Data on operation time measured from the start of circumferential marking to the completion of resection was reported for six studies [7, 14–16, 18, 21]. For seven trials, data on use of sedatives was reported (propofol, midazolam, and morphine) [7, 13–15, 18, 20, 22]. Complications (Perforation, haemorrhage, pneumonia, and emphysema) associated with the procedure were reported for six studies [14, 15, 19–22]. Data on WBC counts and CRP levels were reported in the sixth and seventh studies [7, 14]. Three articles assessed the clinical course (dysphagia, residual gas, and Mallory-Weiss tear) in the two groups after treatment [7, 14, 18].

1.1 Primary outcomes: Abdominal pain. Pain VAS score and percentage of patients without pain was recorded at the following time-points: 1 h, 3 h, 6 h, and 24 h after ESD. Subgroup analyses was performed to assess these two outcomes. (i) Pain VAS score: Six articles reported pain VAS scores at 1 h and 24 h after ESD [7, 16, 18–20, 22]; three articles reported VAS scores at 3 h and 6 h after ESD [7, 16, 18]. The meta-analysis revealed that pain VAS scores at 6 h and 24 h post-procedure in the CO$_2$ insufflation group were significantly lower than those in the air insufflation group ($P = 0.0003$ and $P < 0.00001$, respectively). The difference in VAS scores at 1 h and 3 h after ESD were not statistically significant (Fig 3A). (ii) Percentage of patients without pain: Maeda et al [7] and Kim et al [22] reported the post-procedural pain experience as percentage of patients who did not experience pain at 1 h, 3 h, and 24 h after ESD. Feng et al [21] only reported the rate of pain-free patients at 1 h post-procedure. No significant higher proportion of patients was observed in the air insufflation group at 3 h after ESD; however, the number of patients with pain was significantly smaller in CO$_2$ insufflation group at 1 h and 24 h after ESD (Fig 3B).

1.2 Primary outcomes: PtcCO$_2$. Mean PtcCO$_2$ levels after ESD were reported in five RCTs [7, 13, 14, 17, 18]. Meta-analysis showed no significant between-group difference in this respect ($SMD = -0.02$, 95% CI: -0.22–0.17, $P = 0.81$; $I^2 = 0\%$; Fig 3C).

1.3 Primary outcomes: PaCO$_2$. Mean PaCO$_2$ levels after ESD were reported in four articles [14, 19–21]. Use of CO$_2$ insufflation was not associated with a significant decrease in postoperative PaCO$_2$ ($SMD = -0.08$, 95% CI: -0.34–0.18; Fig 3D). There was no significant heterogeneity among these four articles ($I^2 = 32\%$, $P = 0.54$). In general, the trend was consistent with that of mean PtcCO$_2$ levels after ESD.

2.1 Secondary outcomes: Abdominal distention VAS score. Two studies utilized VAS score to assess abdominal distention at 1 h and 24 h post-procedure [7, 19]. VAS scores at 1 h and 24 h after ESD were higher in the air insufflation group. The between-group difference at
A: Post-procedural abdominal pain VAS score

| Study or Subgroup | Experimental | Control | Mean Difference | Std. Mean Difference |
|-------------------|--------------|---------|-----------------|----------------------|
|                   | Mean (SD)    | Mean (SD) |               | IV (Random, 95% CI)  |
| 01                | 4.3 (3.5)    | 4.5 (3.5) | 0.00 (0.45, 0.45) | IV (Random, 95% CI)  |
| 04                | 18.6 (7.8)   | 18.6 (7.5) | -0.02 (0.08, 0.02) | IV (Random, 95% CI)  |
| 05                | 7.5 (5.2)    | 7.6 (5.1) | -0.01 (0.05, 0.10) | IV (Random, 95% CI)  |
| 07                | 5.4 (3.8)    | 5.5 (3.7) | -0.05 (0.08, 0.05) | IV (Random, 95% CI)  |
| 09                | 24.3 (3.2)   | 24.5 (3.1) | -0.02 (0.05, 0.05) | IV (Random, 95% CI)  |
| 11                | 16.8 (9.0)   | 16.9 (8.9) | 0.01 (0.00, 0.01) | IV (Random, 95% CI)  |
| Subtotal (95% CI) | 27.3 (10.4)  | 27.3 (10.4) | -0.01 (0.02, 0.02) | IV (Random, 95% CI)  |

Heterogeneity: Tau^2 = 0.02, Chi^2 = 3.46, df = 4 (P = 0.48), I^2 = 19.9%

Test for overall effect: Z = 0.24 (P = 0.81)

B: Percentage of patients without pain

| Study or Subgroup | Experimental | Control | Mean Difference | Std. Mean Difference |
|-------------------|--------------|---------|-----------------|----------------------|
|                   | Mean (SD)    | Mean (SD) |               | IV (Random, 95% CI)  |
| 01                | 4.3 (3.5)    | 4.5 (3.5) | 0.00 (0.45, 0.45) | IV (Random, 95% CI)  |
| 04                | 18.6 (7.8)   | 18.6 (7.5) | -0.02 (0.08, 0.02) | IV (Random, 95% CI)  |
| 05                | 7.5 (5.2)    | 7.6 (5.1) | -0.01 (0.05, 0.10) | IV (Random, 95% CI)  |
| 07                | 5.4 (3.8)    | 5.5 (3.7) | -0.05 (0.08, 0.05) | IV (Random, 95% CI)  |
| 09                | 24.3 (3.2)   | 24.5 (3.1) | -0.02 (0.05, 0.05) | IV (Random, 95% CI)  |
| 11                | 16.8 (9.0)   | 16.9 (8.9) | 0.01 (0.00, 0.01) | IV (Random, 95% CI)  |
| Subtotal (95% CI) | 27.3 (10.4)  | 27.3 (10.4) | -0.01 (0.02, 0.02) | IV (Random, 95% CI)  |

Heterogeneity: Tau^2 = 0.02, Chi^2 = 3.46, df = 4 (P = 0.48), I^2 = 19.9%

Test for overall effect: Z = 0.24 (P = 0.81)

C: Mean PtcCO\(_2\) levels

| Study or Subgroup | Experimental | Control | Mean Difference | Std. Mean Difference |
|-------------------|--------------|---------|-----------------|----------------------|
|                   | Mean (SD)    | Mean (SD) |               | IV (Random, 95% CI)  |
| 01                | 4.3 (3.5)    | 4.5 (3.5) | 0.00 (0.45, 0.45) | IV (Random, 95% CI)  |
| 04                | 18.6 (7.8)   | 18.6 (7.5) | -0.02 (0.08, 0.02) | IV (Random, 95% CI)  |
| 05                | 7.5 (5.2)    | 7.6 (5.1) | -0.01 (0.05, 0.10) | IV (Random, 95% CI)  |
| 07                | 5.4 (3.8)    | 5.5 (3.7) | -0.05 (0.08, 0.05) | IV (Random, 95% CI)  |
| 09                | 24.3 (3.2)   | 24.5 (3.1) | -0.02 (0.05, 0.05) | IV (Random, 95% CI)  |
| 11                | 16.8 (9.0)   | 16.9 (8.9) | 0.01 (0.00, 0.01) | IV (Random, 95% CI)  |
| Subtotal (95% CI) | 27.3 (10.4)  | 27.3 (10.4) | -0.01 (0.02, 0.02) | IV (Random, 95% CI)  |

Heterogeneity: Tau^2 = 0.02, Chi^2 = 3.46, df = 4 (P = 0.48), I^2 = 19.9%

Test for overall effect: Z = 0.24 (P = 0.81)

D: post-procedural PaCO\(_2\); SMD with 95% CI

Fig 3. Forest plot of primary outcomes of ESD with CO\(_2\) insufflation and air insufflation. A: post-procedural abdominal pain VAS score; SMD with 95% CI; B: Percentage of patients without pain; RR with 95% CI; C: mean PtcCO\(_2\) levels; SMD with 95% CI; D: post-procedural PaCO\(_2\); SMD with 95% CI.

https://doi.org/10.1371/journal.pone.0177909.g003
1h after ESD was statistically significant (SMD = -1.84, 95%CI: -3.11– -0.57, \( P \) = 0.005; \( I^2 \) = 92%; Fig 4A), while that at 24h after ESD was not statistically significant (SMD = -0.78, 95%CI: -1.85–0.30, \( P \) = 0.16; \( I^2 \) = 92%; Fig 4A).

2.2 Secondary outcomes: Abdominal circumference. Just one study reported the change in abdominal circumference after ESD[22]. Abdominal circumference after ESD was lower in the CO\(_2\) group, though the difference was not statistically significant (SMD = -0.60, 95%CI: -1.46–0.26, \( P \) = 0.17; Fig 4B).

2.3 Secondary outcomes: SpO\(_2\)%. Postoperative SpO\(_2\)% after ESD was also reported by 4 studies[7, 13, 14, 18]. No significant difference in SpO\(_2\)% was observed between the two groups (SMD = 0.13, 95%CI: -0.09–0.35, \( P \) = 0.25; \( I^2 \) = 0%; Fig 4C).

2.4 Secondary outcomes: Procedure time and hospital stay. With regard to procedure time, all of the air group procedures were completed without delay[7, 14–16, 18, 21]. However, use of CO\(_2\) insufflation was associated with significantly shorter procedure time (SMD = 0.21, 95% CI: 0.02–0.40, \( P \) = 0.03; \( I^2 \) = 0%; Fig 4D). None of patients required extended hospitalization[7, 14, 21]. No significant between-group difference was observed with respect to the length of hospital stay (Fig 4E).

2.5 Secondary outcomes: Complications. Perforation, haemorrhage, pneumonia, and emphysema were the main complications in seven studies. The four complications appeared to be balanced between the CO\(_2\) insufflation and the air insufflation groups[14, 15, 18–22]. No significant heterogeneity was observed among these studies (Fig 4F–4I).

2.6 Secondary outcomes: Laboratory examination. No significant between-group difference was observed with respect to WBC counts and CRP levels on day-1 after procedure in two studies [14 (Fig 4] and 4K).
2.7 Secondary outcomes: Sedative drugs. Seven articles reported the dosage of sedative drugs\(^7, 13–15, 18, 20, 22\), which included propofol, midazolam, and morphia. Only Saito et al\(^15\) used midazolam to maintain the depth of sedation, while Takada et al\(^14\) used midazolam in combination with diazepam and pentazocine; the others\(^13, 18, 20, 22\) were all combined other drugs to general anesthesia. Compared to air insufflation, dosage of sedative drugs did not obviously decrease in CO\(_2\) insufflation group, except when midazolam was used alone (Fig 4L–4N).

2.8 Secondary outcomes: Clinical course. The included studies reported the following clinical parameters: residual gas, dysphagia, and Mallory-Weiss tear. Maeda et al reported dysphagia and gas volume in the gastrointestinal tract\(^7, 18\). The residual gas volume in the CO\(_2\) insufflation group was significantly lower than that in the air insufflations group \(P<0.00001\), (Fig 4O); dysphagia occurred in three patients in the air group and two patients in the CO\(_2\) group (Fig 4P). Mallory-Weiss tear was described by Takada et al \(^14\) and Onogi et al\(^17\); the incidence of Mallory-Weiss tear in the CO\(_2\) group was significantly lower than that in the air group \(0\% \text{ vs } 15.6\%, P=0.013\)\(^14\). Onogi et al\(^17\) also reported lower incidence with use of CO\(_2\) insufflation; however, specific data has not been reported.

Subgroup analysis and sensitivity analysis

As for heterogeneity with abdominal pain, abdominal distention and dosage of midazolam, we performed analysis of subgroup on the basis of a combination of drugs, country and type of Endoscope. However, the heterogeneity could not totally eliminate. It may be due to the sedation degree, the skill of endoscopist, etc. We could not conduct subgroup analyses on them as lack of original data. Only two studies\(^13, 14\) reported abdominal distention, which hardly to accomplish the subgroup analysis.

On sensitivity analysis with regard to abdominal pain VAS scores at 1h and 24h post-procedure, heterogeneity decreased slightly after exclusion of the data from the study by L Zhan et al \(^20\) (Tables 2 and 3). It can be speculated that an assistant who was not blinded to the gas being used may have been involved in the outcomes assessment.

Discussion

In this meta-analysis, we assessed the safety and efficacy of CO\(_2\) insufflation versus that of air insufflation for ESD treatment. The key finding of our analysis is that use of CO\(_2\) insufflation was associated with lower abdominal pain and distension in the postoperative period. Moreover, use of CO\(_2\) insufflation was associated with shorter procedure time. Finally, use of CO\(_2\) insufflation offered a distinct advantage of lower residual gas volume in the gastrointestinal tract. However, no advantage of CO\(_2\) insufflation was observed with respect to CO\(_2\) retention, SpO\(_2\)%, the length of hospital stay and abdominal circumference. Overall, this meta-analysis suggests that CO\(_2\) insufflation is a safe and effective alternative to use of air insufflation for ESD.

| Table 2. Changes in the heterogeneity of abdominal pain VAS score at 1h post-procedure after sequential exclusion of one study at a time. |
|---|---|---|
| Expected Data | Heterogeneity (\(I^2\)% | Increase or decrease rate |
| 2 | Maeda et al\(^7\) | 95% | 0% |
| 4 | X Liu et al\(^19\) | 96% | 1% |
| 5 | L Zhan et al\(^20\) | 73% | -23% |
| 7 | Kim et al\(^22\) | 96% | 1% |
| 9 | Mosby et al\(^16\) | 96% | 1% |
| 11 | Maeda et al\(^18\) | 95% | 0% |

https://doi.org/10.1371/journal.pone.0177909.t002
We mainly assessed the extent of post-procedural abdominal discomfort and CO\textsubscript{2} retention. Gas is deliberately insufflated into the gut lumen during ESD to facilitate visualization. In comparison with air, the gastrointestinal mucosa absorbs CO\textsubscript{2} faster, which is subsequently eliminated via the lung. Therefore, CO\textsubscript{2} insufflation possibly decreases the duration of abdominal distension\cite{25}. However, Maeda et al\cite{7} revealed that CO\textsubscript{2} insufflation was irrelevant to the subjective pain and distension of patients. An RCT\cite{14} showed no effect on the number of patients without pain. The results of our meta-analysis suggest that CO\textsubscript{2} insufflation alleviated abdominal pain for at least 6h, and abdominal distension at 1h. Moreover, the percentage of patients without pain was also decreased, although the number of included RCTs was less. Whether CO\textsubscript{2} insufflation induces metabolic disorder such as CO\textsubscript{2} retention and decrease in SpO\textsubscript{2}% remains to be clarified. Actually, all included trials in this meta-analysis showed concordance between the two groups, and the merged results for all individual studies also revealed no significant difference. In addition to CO\textsubscript{2} insufflation, respiratory depression caused by conscious sedation may also lead to CO\textsubscript{2} retention. We also presented the dosage of sedative drugs used. Only Saito et al\cite{15} reported a difference when patients were administered midazolam alone; for the other studies\cite{13, 14, 20, 22} there was no significant between-group difference with respect to dosage of sedative drugs. Moreover, a significant heterogeneity was observed among the studies owing to the use of combination of sedative drugs and the differences with respect to patient’s sedation level.

Until now, two studies\cite{7, 18} have analyzed residual gas; the results bore some similarities to abdominal discomfort caused by rapid absorption into the bloodstream. The study by Takada et al\cite{23} was the first RCT to show that use of CO\textsubscript{2} insufflation for ESD could reduce the risk of Mallory-Weiss tear\cite{14}; similar results were later reported by Onogi et al\cite{17}. The lower incidence of Mallory-Weiss tear in the CO\textsubscript{2} group was ostensibly due to lower tension of the gastric mucosa as a result of residual gas in the stomach. More RCTs are needed to assess this issue. Four complications were reported in the seven studies included in the present meta-analysis\cite{14, 15, 19–22}. When perforation occurs, the gas in the gastrointestinal tract leaks into the peritoneal cavity. Owing to faster absorption of CO\textsubscript{2}, use of CO\textsubscript{2} insufflation is expected to lead to lower intra-abdominal pressure in the postoperative period; however, our meta-analysis showed no significant between-group difference in this respect. Contrary to earlier reports, use of CO\textsubscript{2} insufflation was associated with shorter procedure time than that associated with use of air insufflation. However, more than half of the included studies did not report the experience level of the surgeons, which could have affected the procedure time.

**Limitations**

This meta-analysis has several limitations. First, all included studies were from Asia. Second, several studies excluded patients with severe pulmonary disease. Although Takada et al\cite{23} recently reported the safety of CO\textsubscript{2} insufflation during ESD in patients with pulmonary...
dysfunction under conscious sedation, it was a single-center and uncontrolled study. Other notable limitations of our meta-analysis include heterogeneity among the included studies, inconsistency in the reported outcomes, incomplete data on some of the variables, the relatively small number of included studies and the possibility of publication bias. Some of the outcomes such as abdominal distension are liable to be effected by the depth of sedation and the skills of the endoscopist. Subgroup analyses to assess the effect of these variables could not be performed due to lack of original data. Only two studies reported data on abdominal distension[13, 14]. More robust studies are required to draw definitive conclusions.

**Conclusion**

In conclusion, this meta-analysis indicates that CO\(_2\) insufflation may offer advantages over air insufflation with respect to postoperative abdominal discomfort, procedure time, and the residual gas volume. No significant difference was observed with respect to PtCO\(_2\), PaCO\(_2\), SpO\(_2\)%, abdominal circumference, length of hospital stay, sedation dosage, complications, WBC count, serum CRP level, and dysphagia. More RCTs are required to assess its advantages and necessity in future.

**Supporting information**

**S1 Table. Construction of search strategy.** EMBASE: Excerpta Medica Database; Sinomed: Chinese Biomedical Literature Database; MeSH: Medical Subject Heading; ESD: Endoscopic submucosal dissection.

(DOCX)

**S2 Table. PRISMA 2009 checklist.** Preferred reporting items for systematic reviews and meta-analyses.

(DOCX)

**Acknowledgments**

We would like to gratitude the authors of the studies that have made up the database for this meta-analysis.

**Author Contributions**

**Conceptualization:** XL HD.

**Data curation:** XL HD.

**Formal analysis:** XL HD.

**Funding acquisition:** GZ.

**Investigation:** GZ.

**Methodology:** YZ.

**Project administration:** XL GZ.

**Resources:** XL HD.

**Software:** XL.

**Supervision:** GZ.

**Validation:** XL HD.
Visualization: XL HD.

Writing – original draft: XL.

Writing – review & editing: XL HD.

References

1. Enomoto S, Yahagi N, Fujishiro M, Oka M, Kakushima N, Iguchi M, et al. Novel endoscopic hemostasis technique for use during endoscopic submucosal dissection. Endoscopy. 2007; E156. https://doi.org/10.1055/s-2006-925254 PMID: 16775794

2. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010; 6: 868–871.

3. Yamano HO, Yoshikawa K, Kimura T, Yamamoto E, Harada E, Kudou T, et al. Carbon dioxide insufflation for colonoscopy: evaluation of gas volume, abdominal pain, examination time and transcutaneous partial CO2 pressure. J Gastroenterol. 2010; 12: 1235–1240.

4. Rogers BH. CO2 during colonoscopy for safety and comfort. Gastrointest Endosc. 1985; 2: 108–109.

5. Kikuchi T, Fu KI, Saito Y, Uraoka T, Fukuzawa M, Fukunaga S, et al. Transcutaneous monitoring of partial pressure of carbon dioxide during endoscopic submucosal dissection of early colorectal neoplasia with carbon dioxide insufflation: a prospective study. Surg Endosc. 2010; 9: 2231–2235.

6. Suzuki T, Minami H, Komatsu T, Masusda R, Kobayashi Y, Sakamoto A, et al. Prolonged carbon dioxide insufflation under general anesthesia for endoscopic submucosal dissection. Endoscop y. 2010; 12: 1021–1029.

7. Maeda Y, Hiraseawa D, Fujita N, Obana T, Sugawara T, Ohira T, et al. A prospective, randomized, double-blind, controlled trial on the efficacy of carbon dioxide insufflation in gastric endoscopic submucosal dissection. Endoscopy. 2013; 5: 335–341.

8. Wang WL, Wu ZH, Sun Q, Wei JF, Chen XF, Zhou DK, et al. Meta-analysis: the use of carbon dioxide insufflation vs. room air insufflation for gastrointestinal endoscopy. Aliment Pharmacol Ther. 2012; 10: 1145–1154.

9. Cheng Y, Xiong XZ, Wu SJ, Lu J, Lin YX, Cheng NS, et al. Carbon dioxide insufflation for endoscopic retrograde cholangiopancreatography: A meta-analysis and systematic review. World J Gastroenterol. 2012; 39: 5622–5631.

10. Higgins JPT, Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. 2011.

11. Rosenthal R. Meta-Analysis: Quantitative Methods for Research Synthesis by Fredric M. Wolf. Beverly Hills California Sage Publications. 1986; 1: 77–92.

12. Fellow JPHS. Chapter 9. Analysing Data and Undertaking Meta-Analyses. John Wiley & Sons, Ltd; 2008.

13. Nonaka S, Saito Y, Takisawa H, Kim Y, Kikuchi T, Oda I. Safety of carbon dioxide insufflation for upper gastrointestinal tract endoscopic treatment of patients under deep sedation. Surg Endosc. 2010; 7: 1638–1645.

14. Takada J, Araki H, Onogi F, Nakanishi T, Kubota M, Ibuka T, et al. Safety and efficacy of carbon dioxide insufflation during gastric endoscopic submucosal dissection. World J Gastroenterol. 2015; 26: 8195–8202.

15. Saito Y, Uraoka T, Matsuda T, Emura F, Ikehara H, Mashimo Y, et al. A pilot study to assess the safety and efficacy of carbon dioxide insufflation during colorectal endoscopic submucosal dissection with the patient under conscious sedation. Gastrointest Endosc. 2007; 3: 537–542.

16. Tanioka D, Kawahara Y, Okada H, Takenaka R, Yagi S, Inoue M, et al. Safety and Efficacy of Carbon Dioxide (CO2) Insufflation During Endoscopic Submucosal Dissection (ESD) for Gastric Cancer Under Propofol Sedation: A Randomized, Controlled Trial. Gastrointest Endosc. 2008; 5: B279.

17. Onogi F, Araki H, Nakanishi T, Ibuka T, Shiraki M, Shimizu M, et al. The safety and efficacy of carbon dioxide insufflation in endoscopic submucosal dissection for gastric neoplasms in patients under deep sedation: a prospective study. Journal of Gastroenterology & Hepatology. 2011: 60.

18. Maeda Y, Hiraseawa D, Fujita N, Ohira T, Harada Y, Yamagata T, et al. Carbon dioxide insufflation in esophageal endoscopic submucosal dissection reduces mediastinal emphysema: A randomized, double-blind, controlled trial. World J Gastroenterol. 2016; 32: 7373–7382.

19. Liu X, Wan L, Wang S, Ge N, Wang GX, Guo JT, et al. Safety and efficacy of carbon dioxide insufflation in gastric endoscopic submucosal dissection. China Journal of Endoscopy. 2016.
20. Zhan LL, Zhou HM. Application of carbon dioxide to the upper gastrointestinal endoscopic submucosal dissection. Chinese Journal of Digestive Endoscopy. 2015; 4: 246–249.

21. Feng H, Yujun FU, Niu S, Caifeng MI, Mingming LV. Application of carbon dioxide insufflations in endoscopic submucosal dissection. China Modern Doctor. 2014.

22. Kim SY, Chung JW, Park DK, Kwon KA, Kim KO, Kim YJ. Efficacy of carbon dioxide insufflation during gastric endoscopic submucosal dissection: a randomized, double-blind, controlled, prospective study. Gastrointest Endosc. 2015; 6: 1018–1024.

23. Takada J, Araki H, Onogi F, Nakanishi T, Kubota M, Ibuka T, et al. Safety of carbon dioxide insufflation during gastric endoscopic submucosal dissection in patients with pulmonary dysfunction under conscious sedation. Surg Endosc. 2015; 7: 1963–1969.

24. Bretthauer M, Thiisevensen E, Huppertzhauss G, Gisselsson L, Grotmol T, Skovlund E, et al. NORC-CAP (Norwegian colorectal cancer prevention): a randomised trial to assess the safety and efficacy of carbon dioxide versus air insufflation in colonoscopy. Gut. 2002; 50: 604–607. PMID: 11950803

25. Lord AC, Riss S. Is the type of insufflation a key issue in gastro-intestinal endoscopy? World J Gastroentero. 2014; 9: 2193.